EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil

Gerlinde Maria Michl, Florian M Vogt, Andreas Nouriani, Roland Ladurner, Marcus Kremer, Timo Reisländer, Marlies Michl

Chemotherapy · 2024

DOI: 10.1159/000531525 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Chemotherapy, 2024. Verfasst von Gerlinde Maria Michl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Praxis Dr. Michl, Specialists for Hematology and Oncology, Munich, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Pyrrolidines, Thymine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trifluridine/tipiracil is approved for the use in later or last-line setting in previously treated metastatic colorectal cancer (mCRC) patients who progressed on standard anti-tumor drugs including 5-fluorouracil (5-FU), irinotecan, oxaliplatin, anti-VEGF and anti-EGFR antibodies, or who are not considered candidates for those standard therapies. In this report, we describe a 67-year-old male patient with KRAS-mutated mCRC and metachronous liver and lung metastasis who failed prior 5-FU- and irinotecan-containing regimens, but then showed long-term disease control for 31 months on single-agent trifluridine/tipiracil given as second-line treatment. According to our experience, trifluridine/tipiracil is a feasible and effective treatment option in earlier but not necessarily last-line therapy in mCRC patients who are not considered candidates for doublet or triplet chemotherapy. Besides its efficacy, it is associated with maintained quality of life and a manageable toxicity profile. Considering increasing age of mCRC patients and their wish for maintaining an independent lifestyle, further research on the use of trifluridine/tipiracil in earlier lines of systemic mCRC therapy is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsPyrrolidinesThymineMaleHumansAgedProgression-Free SurvivalUracilTrifluridineIrinotecanQuality of LifeFluorouracilDrug CombinationsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Long-term survivalMetastatic colorectal cancerTrifluridine/tipiracil

Substanzen

tipiracilUracilTrifluridineIrinotecanFluorouracilDrug CombinationsPyrrolidinesThymine

Autor:innen und Institutionen

  • Praxis Dr. Michl, Specialists for Hematology and Oncology, Munich, Germany.
  • RADIOLOGIE München, Specialists for Radiology, Munich, Germany.
  • Joint Practice for Internal Medicine and Gastroenterology, Munich, Germany.
  • Department of Surgery, Hospital Martha-Maria, Munich, Germany.
  • Department of Pathology, Municipal Hospital of Munich, Krankenhaus Neuperlach, Munich, Germany.
  • Institute of Pathology, Technical University of Munich, Munich, Germany.

Zitieren

APA

Michl, G. M., Vogt, F. M., Nouriani, A., Ladurner, R., Kremer, M., Reisländer, T., & Michl, M. (2024). Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil. Chemotherapy. https://doi.org/10.1159/000531525

Vancouver

Michl GM, Vogt FM, Nouriani A, Ladurner R, Kremer M, Reisländer T, et al. Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil. Chemotherapy. 2024. doi:10.1159/000531525

BibTeX
@article{Michl2024,
  author = {Michl, Gerlinde Maria and Vogt, Florian M and Nouriani, Andreas and Ladurner, Roland and Kremer, Marcus and Reisländer, Timo and Michl, Marlies},
  title = {Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil},
  journal = {Chemotherapy},
  year = {2024},
  doi = {10.1159/000531525}
}
Kostenlos starten →